Carole Ho - Nov 25, 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Chief Medical Officer
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Nov 25, 2024
Transactions value $
$12,135
Form type
4
Date filed
11/27/2024, 04:44 PM
Previous filing
Aug 22, 2024
Next filing
Jan 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $12.1K +17.8K +15.02% $0.68 137K Nov 25, 2024 Direct F1
holding DNLI Common Stock 183K Nov 25, 2024 See footnote F2
holding DNLI Common Stock 25K Nov 25, 2024 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -17.8K -14.28% $0.00 107K Nov 25, 2024 Common Stock 17.8K $0.68 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 118,810 Unvested RSUs.
F2 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F3 The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.
F4 The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.